Human PapillomavirusCO-HPVNCT07418203
Knowledge of 18-19 Years Old About Papillomavirus and HPV Vaccination
An observational study of Human Papillomavirus, run by Université de Reims Champagne-Ardenne at 1 site in France.
Trial summary
Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. Read more about this study
- Who is it for?
- Ages 18 to 19 yearsHealthy volunteers can take part
- Conditions the study is for
- Human Papillomavirus
- What is being tested?
- Data collection
- How many people
- 29 participants
- Where
- 1 siteFrance
- Study dates
- 1 Dec 2024to 1 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 19 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: girls and boys aged 18 to 19 years old
Who may be able to join
- Boys and girls 18 to 19 years of age Vaccinated or not against HPV Sexually active or not Agreeing to take part in the study
Who cannot join
- Minors Age 20 and over Protected by law (guardianship, curatorship, safeguard of justice) Not wishing to answer the questionnaire
Trial locations and contacts
1 site in 1 country.
About this study
Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule.
Information, education and communication about HPV are essential to enable the entire population to make informed and responsible decisions about HPV.
Increasing information and immunization coverage for papillomavirus is part of the government's ambitious health plans with the national sexual health strategy and college vaccination campaign.
Read the detailed description
The main objective is to describe knowledge of girls and boys aged 18-19 about papillomavirus and HPV vaccination
- Conditions
- Human Papillomavirus
- Being tested
- Data collection
- Keywords
- HPV, HPV vaccination, knowledge of young
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
Data collection
What is being measured
The primary outcome is the main question the study is designed to answer.
Knowledge about HPV and anti-HPV vaccination
Knowledge about HPV and anti-HPV vaccination will be assessed by a questionnaire developed by a team of midwives and methodologists. Questions will address:
Knowledge about HPV infection Knowledge of prevention measures Knowledge about HPV vaccination
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start1 Dec 2024
- Primary completion1 Feb 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human PapillomavirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Université de Reims Champagne-Ardenne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07418203
- Sponsor's protocol ID
- 2024_RIPH_16_CO-HPV
- Acronym
- CO-HPV
- Status last verified
- Feb 2026
- First submitted
- 6 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Knowledge of 18-19 Years Old About Papillomavirus and HPV Vaccination
- ClinicalTrials.gov ID
- NCT07418203
- Acronym / sponsor ID
- CO-HPV / 2024_RIPH_16_CO-HPV
- Conditions
- Human Papillomavirus
- Keywords
- HPV, HPV vaccination, knowledge of young
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Université de Reims Champagne-ArdenneUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 1 Feb 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule.
Information, education and communication about HPV are essential to enable the entire population to make informed and responsible decisions about HPV.
Increasing information and immunization coverage for papillomavirus is part of the government's ambitious health plans with the national sexual health strategy and college vaccination campaign.
Detailed description
The main objective is to describe knowledge of girls and boys aged 18-19 about papillomavirus and HPV vaccination
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 19 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- girls and boys aged 18 to 19 years old
Key inclusion criteria (1 listed)
- Boys and girls 18 to 19 years of age Vaccinated or not against HPV Sexually active or not Agreeing to take part in the study
Key exclusion criteria (1 listed)
- Minors Age 20 and over Protected by law (guardianship, curatorship, safeguard of justice) Not wishing to answer the questionnaire
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data collectionData collection | Other | – |
Primary outcome
Knowledge about HPV and anti-HPV vaccination
Time frame: Day 0
Knowledge about HPV and anti-HPV vaccination will be assessed by a questionnaire developed by a team of midwives and methodologists. Questions will address: Knowledge about HPV infection Knowledge of prevention measures Knowledge about HPV vaccination
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Human Papillomavirus
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Papillomavirus, run by Université de Reims Champagne-Ardenne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knowledge about HPV and anti-HPV vaccination (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.